Weight-Loss Jabs to Be Rolled Out on NHS to Prevent Heart Attacks and Save Lives

The National Institute for Health and Care Excellence (NICE) has approved the use of semaglutide, commonly known by brand names such as Wegovy and Ozempic for patients who are overweight and already living with heart disease.

Previously, access to such medications was largely restricted to individuals with severe obesity or type 2 diabetes. Now, eligibility is widening to include those with a body mass index (BMI) of 27 or higher who have experienced conditions such as heart attacks, strokes, or other serious circulatory problems.

The policy is grounded in compelling clinical evidence. A major international trial found that semaglutide reduced the risk of heart attacks, strokes, and cardiovascular death by around 20%. Crucially, researchers observed that these benefits appeared even before significant weight loss occurred, suggesting the drug may have a direct protective effect on the heart and blood vessels rather than working solely through weight reduction.

A GP or specialist will check if it is the right option for those already taking other heart medicines, such as statins, and alongside a healthy diet, and patients prescribed Wegovy will be able to self-administer the drug at home using a special pen injector device.

Experts have described the development as a turning point in cardiovascular medicine. Cardiovascular disease remains one of the leading causes of death in the UK, responsible for roughly 170,000 deaths each year. By targeting high-risk patients earlier and more aggressively, health authorities note this approach could prevent thousands of future medical emergencies and reduce long-term strain on the healthcare system.

The NICE says the NHS has reached an agreement with the pharmaceutical company Novo Nordisk that makes the treatment, ensuring it will be cost-effective.

As the NHS prepares to implement the programme in the summer, the move signals a new era in preventative healthcare.